Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer.
Saved in:
| Title: | Co-treatment of Colchicine and Rosiglitazone synergistically inhibits cytokine-driven inflammation and modulates the related hsa-miRNA26a-5p, hsa-miRNA21-5p, and STAT3 expression in non-small cell lung cancer. |
|---|---|
| Authors: | Younes N; Department of Biochemistry, Faculty of Science, Alexandria University, P.O. Box 21511, Alexandria, Egypt., Sadek O; Department of Biochemistry, Faculty of Science, Alexandria University, P.O. Box 21511, Alexandria, Egypt., Sultan A; Department of Biochemistry, Faculty of Science, Alexandria University, P.O. Box 21511, Alexandria, Egypt. dr_asultan@alexu.edu.eg.; Department of Oncology, Georgetown University Medical Center, Washington DC, 20057, USA. dr_asultan@alexu.edu.eg. |
| Source: | Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2026 Jul; Vol. 399 (10), pp. 15163-15182. Date of Electronic Publication: 2026 Apr 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
